šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Verastem, Inc. (VSTM)
NASDAQ: VSTM Ā· Real-Time Price Ā· USD
6.33
-0.53 (-7.73%)
At close: Nov 20, 2026, 4:00 PM EST
6.39
+0.06 (0.95%)
After-hours: Nov 20, 2026, 7:30 PM EST

Company Description

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205.

It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.

In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets.

The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem, Inc.
Verastem logo
CountryUnited States
Founded2010
IPO DateJan 27, 2012
IndustryBiotechnology
SectorHealthcare
Employees102
CEODaniel Paterson

Contact Details

Address:
117 Kendrick Street, Suite 500
Needham, Massachusetts 02494
United States
Phone781 292 4200
Websiteverastem.com

Stock Details

Ticker SymbolVSTM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001526119
CUSIP Number92337C203
ISIN NumberUS92337C2035
Employer ID27-3269467
SIC Code2834

Key Executives

NamePosition
Daniel W. PatersonPresident, Chief Executive Officer and Director
Daniel CalkinsChief Financial Officer
Dr. Michael Glen Kauffman M.D., Ph.D.President of Development and Director
Dr. Robert A. Weinberg Ph.D.Co-Founder and Chair of Scientific Advisory Board
Dr. Michelle Detwiler M.D., Ph.D.Co-Founder
Lori HorvatExecutive Vice President of Portfolio Strategy and Operations
Dr. Jonathan Pachter Ph.D.Chief Scientific Officer
Julissa VianaSenior Vice President of Corporate Communications, Investor Relations and Patient Advocacy
Mark J. WandaSenior Vice President of Legal and Chief Compliance Officer
Cathy CarewChief Organizational Effectiveness Officer

Latest SEC Filings

DateTypeTitle
Nov 19, 20268-KCurrent Report
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 10, 2026SCHEDULE 13GFiling
Nov 5, 2026S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuers
Nov 5, 2026S-8Securities to be offered to employees in employee benefit plans
Nov 5, 20268-KCurrent Report
Nov 5, 202610-QQuarterly Report
Oct 30, 2026SCHEDULE 13G/AFiling
Oct 14, 20268-KCurrent Report
Oct 14, 2026424B5Filing
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides